Literature DB >> 33891698

Exosomal lncRNA-p21 derived from mesenchymal stem cells protects epithelial cells during LPS-induced acute lung injury by sponging miR-181.

Xintong Sui1, Wei Liu1, Zhi Liu1.   

Abstract

Long noncoding RNAs (lncRNAs) act as essential regulators of various diseases. However, the functions of lncRNAs in sepsis-induced acute lung injury (SALI) remain unclear. Here, we found that lipopolysaccharide could upregulate lncRNA-p21 expression in mesenchymal stem cells (MSCs) in a time- and dose-dependent manner and that lncRNA-p21 was packaged into exosomes. Furthermore, we demonstrated that treatment with exosomal lncRNA-p21 could increase the expression of sirtuin 1 (SIRT1) to protect MLE-12 cells from apoptosis during sepsis. Moreover, we identified SIRT1 as a direct target of miR-181 and found that the level of SIRT1 was negatively correlated with the level of miR-181. The luciferase reporter assay also confirmed the negative correlation between the levels of miR-181 and lncRNA-p21. Our results showed that the lncRNA-p21-induced downregulation of miR-181 might suppress epithelial cell apoptosis and alleviate lung tissue injury by upregulating SIRT1 expression, suggesting the potential therapeutic effects of lncRNA-p21 on SALI. In conclusion, we found that the novel lncRNA-p21/miR-181/SIRT1 pathway may play an important role in the progression of SALI, and MSC-derived exosomes may be a new therapeutic strategy for this disease.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  SIRT1; acute lung injury; exosomes; lncRNA-p21; miR-181

Year:  2021        PMID: 33891698     DOI: 10.1093/abbs/gmab043

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  7 in total

Review 1.  Molecular Insight into the Therapeutic Effects of Stem Cell-Derived Exosomes in Respiratory Diseases and the Potential for Pulmonary Delivery.

Authors:  Mohammad H Azhdari; Nima Goodarzi; Mohammad Doroudian; Ronan MacLoughlin
Journal:  Int J Mol Sci       Date:  2022-06-03       Impact factor: 6.208

2.  lncRNA IGF2-AS Regulates Nucleotide Metabolism by Mediating HMGA1 to Promote Pyroptosis of Endothelial Progenitor Cells in Sepsis Patients.

Authors:  Guibin Liang; Menghao Zeng; Min Gao; Wei Xing; Xin Jin; Qianlu Wang; Longtian Deng; Hao Ou; Zhihui He
Journal:  Oxid Med Cell Longev       Date:  2022-01-17       Impact factor: 6.543

3.  Differential Lung Protective Capacity of Exosomes Derived from Human Adipose Tissue, Bone Marrow, and Umbilical Cord Mesenchymal Stem Cells in Sepsis-Induced Acute Lung Injury.

Authors:  Huimin Deng; Lina Zhu; Yiguo Zhang; Li Zheng; Song Hu; Wenyu Zhou; Tong Zhang; Wenting Xu; Yuanli Chen; Huanping Zhou; Quanfu Li; Juan Wei; Hao Yang; Xin Lv
Journal:  Oxid Med Cell Longev       Date:  2022-02-27       Impact factor: 6.543

4.  Protective effect of dexmedetomidine in cecal ligation perforation-induced acute lung injury through HMGB1/RAGE pathway regulation and pyroptosis activation.

Authors:  Huaqin Sun; Hongyi Hu; Xiaoping Xu; Mingsun Fang; Tao Tao; Zhehao Liang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 5.  Extracellular Vesicles, New Players in Sepsis and Acute Respiratory Distress Syndrome.

Authors:  Wenqiang Jing; Huijuan Wang; Liying Zhan; Wei Yan
Journal:  Front Cell Infect Microbiol       Date:  2022-04-07       Impact factor: 6.073

6.  Antisense Oligonucleotide-Based Therapy on miR-181a-5p Alleviates Cartilage Degradation of Temporomandibular Joint Osteoarthritis via Promoting SIRT1.

Authors:  Hexu Qi; Zhenxing Zhao; Lin Xu; Yue Zhang; Yifei Li; Li Xiao; Yu Li; Zhihe Zhao; Jie Fang
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

Review 7.  Advances in the use of exosomes for the treatment of ALI/ARDS.

Authors:  Chang Liu; Kun Xiao; Lixin Xie
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.